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Gijs Van Pottelbergh1,2,3*, Wendy PJ Den Elzen4, Jan Degryse1,2 and Jacobijn Gussekloo4Abstract
Background: The prevalence of chronic kidney disease is high in the elderly, but the effects of a decrease in the
eGFR on mortality and functioning are still unclear. The aim of this study was to determine whether the
combination of the eGFR and the eGFR slope is a predictor of mortality and functional decline.
Methods: The eGFR (MDRD equation) and the eGFR slope were calculated. The slope was calculated using four
annual eGFR measurements taken from 85 to 88 years of age. Mortality and changes in the Mini-Mental State
Examination (MMSE), the Geriatric Depression Scale (GDS-15) and the Activities of Daily Living (ADL) scores were
analysed as outcomes from 88 years onwards.
Results: 378 persons aged 88 years participating to the Leiden 85 plus study, an observational prospective cohort
study in the general population, were included. A combined analysis of the baseline eGFR and the eGFR slope showed
that an eGFR of >60 ml/min combined with an eGFR decrease of ≥ 3 ml/min/year and an eGFR of <60 ml/min
combined with an of eGFR decrease ≥5 ml/min/year were independent predictors of increased mortality. The baseline
eGFR, the eGFR slope and a combination of both factors did not predict changes in the MMSE, GDS or ADL scores
between 88 and 90 years.
Conclusion: The combination of the eGFR and the eGFR decrease allows the identification of subgroups of very
elderly with increased mortality risks and of subgroups of very elderly with an eGFR of <60 ml/min without an
increased risk of mortality.
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Demographic predictions for Western countries estimate
that the number of persons aged 80 and over will
increase significantly in the next several decades [1].
Knowing which factors correlate with higher mortality
within this group would allow stratification into high
and low risk groups and could result in different
therapeutic approaches for different risk groups.
The prevalence of chronic kidney disease (CKD) in
older persons is high and increases with advancing age
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distribution, and reproduction in any mediumfiltration rate (eGFR) <60 ml/min/1,73 m2) is >38% in
community-dwelling older persons aged 70 and over.
[3-6] As a result, physicians must treat large numbers of
older persons with CKD.
A low eGFR has been associated with higher mortality
risk [7,8]. The results of the Cardiovascular Health Study
[9,10], a study in persons (mean age 72 years) with
relatively high cardiovascular risk, indicate that a decrease
in the eGFR is an important risk predictor of mortality.
Other studies have reported a relationship between the
presence of CKD and a decline in activities of daily living
(ADL) in addition to this increase in mortality [11,12].
However, whether the eGFR slope or the combination
of the eGFR and the eGFR slope is a good predictor of
mortality or of a decline in functional performance in
the very elderly in the general population remainsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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risk patients is a necessary step before testing the effect
of interventions in elderly with CKD. In this study, we
investigated whether the combination of the eGFR and
the eGFR slope predicted mortality and functional decline
in the very elderly in the general population at large.
Methods
Study population
The present study was carried out as part of the Leiden
85-plus Study, a population-based prospective follow-up
study of 85-year-old inhabitants of Leiden, the Netherlands.
The study population has been described in detail previ-
ously [13]. Between September 1997 and September 1999,
all inhabitants of Leiden in the 1912–1914 birth cohort
were eligible for study participation. No individual was
excluded on the basis of health, cognitive function or
living situation. All participants gave their informed
consent to take part in the study. For those who had severe
cognitive impairment, informed consent was obtained
from a proxy. The Medical Ethics Committee of the Leiden
University Medical Center approved the study.
Participants were visited annually (from age 85 through
90 years) at their place of residence to gather information
in face-to-face interviews and to obtain venous blood
samples.
In the present study, the baseline eGFR was obtained
at the age of 88 years, and the eGFR slope was calculated
using the four creatinine measurements taken from age
85 to age 88.
Primary study parameters
eGFR and eGFR slope
At study entry and at yearly intervals thereafter, the
serum creatinine and serum albumin concentration was
measured automatically according to the Jaffe method
(Hitachi 747; Hitachi, Tokyo, Japan). The eGFR was
calculated using the 4-variable MDRD equation [14]. All
eGFR values in are expressed in ml/min/1.73 m2 but
are noted as ml/min. A simplified version of the CKD
classification system of the US National Kidney Foundation
[15] was used to divide the study population into three
eGFR-based groups (≥60, between 45 and 59 and < 45 ml/
min/1.73 m2).
The slope of the eGFR (ml/min/1.73 m2/year) over a
period of 3 years for every participant was calculated
by the ordinal least square method using exactly 4
eGFR values (at ages 85, 86, 87 and 88 years). Patients
were divided in subgroups based on the slope of the
change in the eGFR between age 85 and age 88 using
predefined subgroups of >−1, -3 to −1, -5 to −3 and < −5
ml/min/1.73 m2/year. All eGFR slopes in this article
are expressed in ml/min/1.73 m2/year but are noted
as ml/min/year.Mortality
Mortality data, recorded from the start of the study until
Feb. 1, 2010, were obtained from the municipal registry.
Causes of death were obtained from Statistics Netherlands
and are coded according to the International Classification
of Diseases and Related Disorders, 10th revision. Causes
of death were divided into cardiovascular causes (codes
I00–I99) and non-cardiovascular causes (all other codes).
Functional status
Cognitive function was measured using the Mini-Mental
State Examination (MMSE) [16]. The MMSE scores
range from 0 to 30, with lower scores indicating impaired
cognitive function. Depressive symptoms were assessed
using the 15-item Geriatric Depression Scale (GDS), [17].
Scores range from 0 (optimal) to 15. The GDS was only
administered to participants who had a Mini-Mental State
Examination score greater than 18 points.
Disability in daily living was measured with the Activities
of Daily Living (ADL) Scale, which assesses an individual’s
competence by combining the scores for 9 activities of daily
living. [18]. Higher ADL scores indicate more disability.
Comorbidity
We obtained information on the presence of disease at
baseline from the participants’ general practitioners, nursing
home physicians, pharmacy records, laboratory findings
and ECGs. The diseases of interest included stroke,
myocardial infarction (MI) and diabetes mellitus. We
considered diabetes mellitus to be present if diagnosed
by the treating physician, if the non-fasting glucose level
was greater than 11.0 mmol/L, or if a participant was
taking anti-diabetic medication.
Other parameters
During the interview, we obtained information on other
variables, including sex, weight, level of education, income
and residence in a nursing home.
3 Statistical analyses
Baseline differences between the three eGFR-based groups
at age 88 were assessed using the Chi square test for
categorical parameters, one-way ANOVA for normally
distributed variables or the Kruskal-Wallis test for non-
normally distributed variables.
A Cox proportional hazards model was used to study
the relationship between mortality from age 88 onwards
and the different eGFR and eGFR slope categories.
Because we focused on the predictive value of the eGFR
and the eGFR slope and not on the underlying aetiology,
we present Cox proportional hazards models only
including gender. When the eGFR slope was used to
divide participants into subgroups, we adjusted for gen-
der and the mean of the eGFRs at ages 85 and 88. The
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the eGFR at baseline and regression to the mean effects.
For all subgroups, the HRs for total, cardiovascular and
non-cardiovascular mortality were calculated relative to
the participants with an eGFR slope of >−1 ml/min/year.
Two sensitivity analyses were performed correcting for
gender, history of MI and eGFR at baseline (sensitivity
analysis 1) and gender, history of MI and change in weight
between the age of 85 and 88 (sensitivity analysis 2).
The relationships between the eGFR, the eGFR slope
and the combination of both factors and the mean changes
in the MMSE, GDS or ADL scores between age 88 and 90
were evaluated. Differences in the changes in these scores
between different subgroups based on the eGFR and the
eGFR slope were analysed with one-way ANOVA.
All analyses were performed with SPSS software
(version 19.0 SPSS Inc., Chicago, USA).
Results
Study population
Between September 1997 and September 1999, 705 inhab-
itants of Leiden reached the age of 85 years and were
eligible for participation in the study. Fourteen individuals
died before enrolment in the study, and 92 refused to
participate. Of those enrolled in the study, 7 died before
blood samples could be collected, and 30 were unwilling
to provide a blood sample. As a result, blood samples
from 562 subjects were available for analysis at age 85.
Figure 1 shows the number of participants at the outset ofFigure 1 Flow chart of the Leiden 85-plus study.the study and annually thereafter over the 5-year follow-up
period. Blood samples from 378 participants at 85, 86,
87 and 88 years were available for the calculation of the
slope of the change in the eGFR between 85 and 88;
these participants were included in the present study.
The characteristics of the 184 participants who died
before age 88 (n=137) refused to participate before the age
of 88 (n=40) or had no four creatinine measurements
(n=7) are shown in Table 1.
eGFR and eGFR slope
The mean eGFR at baseline (age 88) was 59 ml/min for
the whole population; 45% of the participants had an
eGFR > 60 ml/min, 39% had an eGFR between 45 and
59 ml/min, and 16% had an eGFR<45 ml/min. At age
88, 89 or 90 none of the participants had an eGFR<10
ml/min. The mean slope of the eGFR of the whole
population was −0.4 (SD 3.1) ml/min/year. Among the
subgroups identified, the mean slopes were 0.8 (SD 2.9)
ml/min/year for those with an eGFR of >60 ml/min, -1.1
(SD 2.5) ml/min/year for those with an eGFR of 45–60
ml/min and −2.3 (SD 2.9) ml/min/year for those with an
eGFR of <45 ml/min.
Baseline characteristics
The baseline characteristics of the study population as a
whole and for the three subgroups based on the eGFR at
baseline are shown in Table 2.
The percentage of males was highest in the group with
an eGFR >60 ml/min. No differences in demographicTable 1 Characteristics at age 85 of the study population
(n=378) and the participants who died (n=137) or refused
participation before the age of 88 years (n=40) or had










Male Sex (%) 113 (30%) 73 (40%) <0.01
Low level of education (%) 234 (62%) 129 (70%) <0.01
Low income (%) 194 (51%) 92 (50%) 0.62
Institutionalised 48 (13%) 51 (28%) <0.01
eGFR at age 85 (ml/min/1.73m²)
>60 169 (44%) 73 (40%)
45-60 147 (39%) 69 (38%)
<45 62 (16%) 42 (23%) 0.02
Functional score (median (IQR))
MMSE 25 (19-25) 24 (18-24) <0.01
GDS 2 (0-5) 2 (1-4) 0.01
ADL 12 (9-17) 13 (10-19) <0.01
Table 2 Baseline characteristics at age 88 of the whole study population and of the subgroups based on the eGFR
(calculated by the MDRD equation)
all (n=378) eGFR at age 88 years p*
≥60 (n=169) 45-59 (n=147) <45 (n=62)
Socio-demographics
Male sex (%) 113 (30%) 61 (36%) 37 (25%) 15 (24%) 0.03
Low level of education (%) 231 (61%) 95 (56%) 98 (67%) 39 (63%) 0.50
Low income (%) 194 (51%) 81 (49%) 77 (52%) 36 (58%) 0.16
Institutionalised (%) 48 (13%) 20 (12%) 13 (9%) 15 (24%) 0.07
Comorbidity
Diabetes mellitus (%) 48 (13%) 25 (15%) 16 (11%) 7 (11%) 0.42
CVA in history (%) 38 (10%) 16 (10%) 15 (10%) 7 (11%) 0.68
MI in history (%) 36 (10%) 10 (6%) 14 (10%) 12 (19%) <0.01
Anthropometric and nutrition parameters (mean (SD))
Weight 68 (13) 67 (15) 69 (13) 68 (14) 0.59
Serum Albumin 41 (3) 41 (4) 41 (3) 41 (3 0.06
Functional scores (median (IQR))
MMSE 25 (19-25) 25 (19-27) 26 (21-28) 24 (18-28) 0.30
GDS 2 (0–5) 3 (1-5) 1 (0–3) 2 (1-5) 0.20
ADL 12 (9-17) 13 (9-20) 11 (9-15) 14 (9-16) 0.20
*p was estimated by the Chi square test for categorical parameters, one-way ANOVA for normally distributed parameters and the Kruskal-Wallis test for non-
normally distributed parameters.
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tionalisation or in the prevalences of diabetes mellitus
and a history of CVA were observed between the three
eGFR groups at baseline. A history of MI was more
common in those with low eGFRs (p<0.01). The MMSE
scores and GDS scores did not differ between the eGFR
groups.
Baseline eGFR and mortality
From age 88 years onwards, 318 deaths; occurred in this
cohort.
All participants were followed until 1/02/2010. 46
participants died at age 88–89, 41 at age 89–90, 50 at
age 90–91, 37 at age 91–92, 41 at age 92–93, 36 at age
93–94, 39 at age 94–95. Of the 88 participants still alive
at age 95, 28 participants died before 1/02/2010 and 60
participants aged 95–97 were still alive at this censordate.
Of these deaths 108 were from cardiovascular causes, and
210 were from non-cardiovascular causes.
Compared with participants with an eGFR >60 ml/min
at age 88 (reference), participants with an eGFR <45 ml/
min had a similar gender adjusted total mortality risk
(HR 0.96 (95% CI 0.67-1.37)) and cardiovascular mortality
risk (HR 1.50 (95% CI 0.85-2.62)). In participants with an
eGFR between 45 and 59 ml/min, the gender adjusted
overall (HR 0.99 (95% CI 0.73-1.32) and cardiovascular
(HR 1.05 (95% CI 0.62-1.78) mortality risks were similar
to those of participants with an eGFR >60 ml/min.eGFR slope and mortality
Figure 2 shows the hazard ratios (adjusted for gender
and the mean of the eGFRs at age 85 and 88) for total,
cardiovascular and non-cardiovascular mortality for all
participants according to the eGFR slope using cut-offs
of −5, -3 and −1 ml/min/year. The highest total mortality
and cardiovascular mortality risks were observed for
participants with a decrease of 5 ml/min/year or more
in the eGFR. No between-group differences in non-
cardiovascular mortality were found.
eGFR, eGFR slope and its relationship with mortality
The relationship between the combination of the eGFR
(in 3 subgroups) and the eGFR slope (in 4 subgroups
using cut-offs of −5, -3 and −1 ml/min/year) and mortality
is shown in Table 3.
Participants with eGFR >60 ml/min and eGFR decrease
of ≥3 ml/min/year, participants with eGFR 45–59 ml/min
and eGFR decrease of ≥5 ml/min and participants with an
eGFR of <45 ml/min and an eGFR decrease of ≥5 ml/
min/year had a higher total and cardiovascular mortality
risk than the group of participants with an eGFR decrease
of <1 ml/min/year.
Two sensitivity analyses were performed to further ana-
lyse this relation between mortality and the combination
of the eGFR and eGFR decrease. A first sensitivity analysis
(see Table 4) corrects for the eGFR at baseline and gender.
This analysis shows similar result as Table 3.
Figure 2 All-cause, cardiovascular and non-cardiovascular mortality depending on the change in the eGFR per year among 378
participants aged 88 years at baseline expressed as hazard ratios (HR) adjusted for gender with 95% CIs. Values greater than 1.0 indicate
an increased risk.
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and changes in weight and eGFR changes were analyzed
since (changes in) weight correlates to (changes in)
muscle mass which correlates with the serum creatinine
level. No relation was found between decrease in eGFR
between 85 and 88 years and weight at age 88 (p for trendTable 3 Relationships between both the eGFR at age 88 year
(between age 85 and 88) and total and cardiovascular (CV) m
eGFR slope pe
>−1
eGFR at age 88 > 60 (n=169) n=128
Overall mortality 1 (ref)
CV mortality 1 (ref)
eGFR at age 8845–59 (n=147) n=71
Overall mortality 1 (ref)
CV mortality 1 (ref)
eGFR at age 88 < 45 (n=62) n=20
Overall mortality 1 (ref)
CV mortality 1 (ref)
The results are presented as the HR (95% CI) and were adjusted for gender and the
reference group for each eGFR subgroup.
* No events.0.56) or change in weight (p for trend 0.15) between 85
and 88 years. In a second sensitivity analysis (see Table 5)
change in weight between age 85 and 88, a MI in the
history and gender were used as co- variables. This second
sensitivity analysis showed similar results as Table 3 with
even higher HR for the high risk groupss and the decrease in the eGFR 3 years before
ortality
r year between 85 and 88 years in ml/min/1.73 m2/year
−1 to −2.99 −3 to −4.99 <−5
n=26 n=12 n=3
1.37 (0.82-2.31) 2.17 (1.08-4.40) 2.63 (0.79-8.76)
1.10 (0.39-3.05) 2.99 (1.02-9.07) 8.35 (2.15-32.46)
n=46 n=21 n=9
0.77 (0.47-1.26) 1.27 (0.69-2.35) 3.16 (1.44-6.95)
0.89 (0.38-2.07) 0.67 (0.18-2.78) 4.23 (1.22-14.65)
n=21 n=14 n=7
0.63 (0.31-1.26) 0.54 (0.18-1.61) 2.03 (0.59-7.02)
0.99 (0.39-2.55) 0.34 (0.04-2.76) 4.72 (1.21-18.47)
mean of the eGFR at ages 85 and 88. The results are shown with one
Table 4 Sensitivity analysis 1 of the relationships between both the eGFR at age 88 years and the decrease in the
eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality
eGFR slope per year between 85 and 88 years in ml/min/1.73 m²/year
>-1 -1 to -2.99 -3 to -4.99 <-5
eGFR at age 88 > 60 (n=169)
n=128 n=26 n=12 n=3
Overall mortality 1 (ref) 1.35 (0.81-2.25) 2.09 (1.07-4.09) 2.43 (0.74-8.03)
CV mortality 1 (ref) 1.12 (0.41-3.08) 3.16 (1.12-8.90) 8.99 (2.34-34.60)
eGFR at age 88 45-59 (n=147)
n=71 n=46 n=21 n=9
Overall mortality 1 (ref) 0.70 (0.43-1.15) 1.07 (0.56-2.05) 2.31 (1.06-5.06)
CV mortality 1 (ref) 0.79 (0.34-1.88) 0.55 (1.39-2.12) 2.87 (0.84-9.82)
eGFR at age 88 < 45 (n=62)
n=20 n=21 n=14 n=7
Overall mortality 1 (ref) 0.60 (0.29-1.23) 0.48 (0.16-1.40) 1.77 (0.52-6.10)
CV mortality 1 (ref) 0.91 (0.34-2.39) 0.31 (0.04-2.42) 4.00 (1.04-15.43)
The results are presented as the HR (95% CI) and were adjusted for the eGFR at age 88 and gender. The results are shown with one reference group for each
eGFR subgroup.
* No events.
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The mean changes in the functional scores (MMSE,
GDS and ADL) between 88 and 90 years for the study
population divided into subgroups based on the eGFR
(3 subgroups), on the eGFR slope (4 subgroups using
cut-offs of −5, -3 and −1 ml/min/year) and on a combin-
ation of the two are shown in Table 6. No relationship was
observed between the baseline eGFR, the eGFR slope or a
combination of the two and the mean change in the
MMSE, GDS or ADL score between the age of 88 and 90.
Discussion
The present study shows that combining the eGFR and
the eGFR slope allows the identification of very elderly
with a highly increased mortality risk in the general
population. The highest mortality in every eGFR group
was found in the participants with the largest decrease in
the eGFR. Adjustment for changes in weight over time, asTable 5 Sensitivity analysis 2 for the relationships between b
eGFR 3 years before (between age 85 and 88) and total and c
eGFR s
>-1
eGFR at age 88 > 60 (n=169)
n=128
Overall mortality 1 (ref)
CV mortality 1 (ref)
eGFR at age 88 45-59 (n=147)
n=71
Overall mortality 1 (ref)
CV mortality 1 (ref)
eGFR at age 88 < 45 (n=62)
n=20
Overall mortality 1 (ref)
CV mortality 1 (ref)
The results are presented as the HR (95% CI) and were adjusted for the change in w
shown with one reference group for each eGFR subgroup.
* No events.proxy for changes in muscle mass with correlates well
with serum creatinine values, did not change the results.
Our findings confirm the results of earlier studies [10,19]
in younger populations that showed that the subgroup of
participants with the largest decrease in the eGFR had the
highest mortality rates.
Interestingly, analysing our results in subgroups pro-
vided more detailed insight into the relationships between
the eGFR and the slope of the eGFR on mortality in
the very elderly. Participants in our study with an eGFR
of ≥60 ml/min and a decrease in eGFR of >3 ml/min/year
had a more than twofold higher cardiovascular mortality
risk than participants with normal eGFR and a decrease
of < 1 ml/min/year. Therefore, eGFR decrease could be
used in older persons without CKD to identify individuals
with a higher risk of cardiovascular mortality.
Among participants with eGFRs of 45–60 ml/min, only
those with an eGFR decrease of 5 ml/min/year (6% of theoth the eGFR at age 88 years and the decrease in the
ardiovascular (CV) mortality
lope per year between 85 and 88 years in ml/min/1.73 m²/year
-1 to -2.99 -3 to -4.99 <-5
n=26 n=12 n=3
1.44 (0.85-2.44) 2.77 (1.35-5.68) 4.41 (1.27-15.33)
1.32 (0.48-3.67) 4.08 (1.39-11.96) 10.35 (2.46-43.61)
n=46 n=21 n=9
0.89 (0.53-1.52) 1.58 (0.84-2.96) 3.37 (1.51-7.52)
0.95 (0.38-2.37) 0.83 (0.22-3.09) 4.41 (1.24-15.78)
n=21 n=14 n=7
0.74 (0.36-1.51) 0.50 (0.17-1.46) 2.26 (0.64-8.03)
0.97 (0.37-2.54) 0.29 (0.04-2.32) 4.04 (1.01-16.20)
eight between 85 and 88 years, history of MI and gender. The results are
Table 6 Relationships between the baseline eGFR (at age 88 years), the eGFR slope (between age 85 and 88 years) and
a combination of these two parameters and changes in the MMSE, GDS and ADL scores between age 88 and 90 years
All participants eGFR slope per year between 85 and 88 years
in ml/min/1.73 m²/year
P for the eGFR slope per year
>-1 -1 to -2.99 -3 to -4.99 <-5
Mean change in the MMSE score (+SE)
All participants (n=274) -1.59 (0.22) -1.30 (0.28) -1.74 (0.40) -2.39 (0.63) -2.55 (1.49) 0.33
eGFR 88 > 60 -1.30 (0.30) -1.09 (0.35) -2.31 (0.75) -2.00 (1.41) -1.50 (1.5) 0.27
eGFR 88: 45-60 -1.55 (0.32) -1.42 (0.45) -1.14 (0.54) -2.38 (0.99) -3.14 (1.42) 0.39
eGFR 88 < 45 -2.66 (0.77) -2.33 (1.71) -2.62 (0.99) -2.75 (1.22) -4.50 (7.50) 0.95
P (trend) for eGFR subgroups 0.13 0.50 0.27 0.92 0.46
Mean change in the GDS score (+SE)
All participants (n=198) 0.68 (0.20) 0.82 (0.30) 0.51 (0.24) 0.70 (0.68) -0.40 (1.12) 0.76
eGFR 88 > 60 1.05 (0.36) 1.09 (0.45) 1.14 (0.64) 1.00 (1.41) -1.00 (3.00) 0.86
eGFR 88: 45-60 0.50 (0.24) 0.59 (0.43) 0.37 (0.30) 0.67 (0.56) 0.00 (1.00) 0.95
eGFR 88 < 45 -0.5 (.59) -0.50 (0.56) 0.10 (0.43) 0.33 (3.93) / 0.88
P (trend) for eGFR subgroups 0.22 0.43 0.33 0.96 0.72
Mean change in the ADL score (+SE)
All participants (n=274) 3.58 (0.35) 3.88 (0.48) 3.12 (0.64) 3.42 (1.04) 3.0 (1.17) 0.79
eGFR 88 > 60 3.77 (0.56) 4.04 (0.67) 2.95 (1.35) 2.86 (1.67) 2.50 (2.50) 0.86
eGFR 88: 45-60 3.05 (0.59) 3.24 (0.68) 2.57 (0.72) 2.44 (1.62) 3.43 (1.77) 0.89
eGFR 88 < 45 5.05 (1.10) 5.42 (2.18) 4.75 (1.87) 5.88 (1.89) 2.00 (1.00) 0.91
P (trend) for eGFR subgroups 0.12 0.49 0.42 0.39 0.90
Of the 378 participants at age 88 years, 87 died before age 90 and 17 refused to participate further. The GDS scores were not available for 76 participants who
had at least once a low MMSE score in the annual measurements between 88 and 90 years old.
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had an increased mortality risk. Possible hypotheses for
these differences in thresholds could be that a decrease of 3
ml/min /year or more in persons with eGFR>60 ml/min is
reflecting on-going cardiovascular damage whereas a de-
crease of 1–5 ml/min/year in persons with eGFR<60ml/
min could be explained as fluctuation in eGFR due to
adaptation instead of on-going cardiovascular damage.
These results show that only a very small subgroup of
the participants with an eGFR of 45–60 ml/min had an
increased mortality risk. The current CKD classification
[15] classifies all patients with an eGFR of 45–60 ml/min
as having moderate CKD. Based on the results of our
study, one may wonder whether very elderly individuals
with an eGFR of 45–60 ml/min really should be labelled
as having “moderate stage 3 chronic kidney disease”, as
indicated in the currently used classification of CKD [15].
Earlier studies [7,8] showed that all patients with an
eGFR of <45 ml/min had an increased (cardiovascular)
mortality risk. A recent meta-analysis by Hallan et al.
[20] showed that lower eGFR is independently associated
with mortality and ESRD in all age groups. However, in
older age mortality showed lower relative risk, but higher
absolute risk differences. In our study, 94% (138/147) of
the participants with eGFRs of 45–60 ml/min and 89%(55/62) of the participants with eGFRs of <45 ml/min had
no increase in total or cardiovascular mortality compared
with the participants with eGFR>60 ml/min and eGFR
slope >−1 ml/min/year. This finding is relevant since it
seems possible to select high risk and low risk older
persons based on their eGFR and eGFR decrease, both
easy to measure. Further research should investigate
the benefit of interventions (like cardiovascular risk
management or referral to a nephrologist) in the very
elderly and higher mortality risk.
Finally, earlier research showed that there is an asso-
ciation between a low eGFR and more rapid cognitive
decline [21], frailty [22] and ADL disability [11,12]. In
this study, no relationship was found between the eGFR,
the decrease in the eGFR or a combination of the two and
a change in the MMSE, GDS or ADL score. It is unclear
why the baseline eGFR combined with the eGFR slope
predicted mortality but not changes in functional per-
formance. One possible reason for this could be the small
number of participants in some subgroups in our study.
However, earlier analyses in the Leiden 85-plus Study
cohort [23,24] showed significant differences in functional
performance over time using the same functional per-
formance scores that were used in this study. Therefore,
we consider it unlikely that the lack of association could
Van Pottelbergh et al. BMC Geriatrics 2013, 13:61 Page 8 of 9
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not sensitive to small changes between the age of 88 and
90 Another possible explanation is that participants with a
rapid decrease in the eGFR die before developing
functional decline.Strengths and weaknesses
One strong point of this study is that it was a prospective
study with a cohort of very old persons in a population-
based setting with long, almost complete, follow-up.
Another strength is that the eGFR slopes were calculated
using four eGFR values from every patient. Thus, the well
documented effect [25] of biological and analytical variance
on the slope of the eGFR was minimised. Another strong
point is that we did not use only one cut-off of −3 ml/min/
year but rather analysed the relationship between the eGFR
slope and mortality using 2 additional cut-offs (−5 and −1
ml/min year), allowing us to differentiate a limited decrease
from larger decrease in the eGFR.
One limitation of the study is that the eGFR was esti-
mated with the 4-variable MDRD equation. This equation
is currently recommended in most international guidelines
and a reflection of general practice, [26] but is inadequately
validated in patients age 80 and older[27]. The CKD_EPI
creatinine based equation [28] which needs Isotope Dilu-
tion Mass Spectrometry (IDMS) is slightly better in esti-
mating the eGFR in older persons [29,30]. However, in this
study we did not perform the creatinine measurements
with the required IDMS [31] but the Jaffe method, which
was recommended at the time the data collection started.
Since the MDRD equation uses non-IDMS creatinine to
estimate the eGFR, the MDRD equation was used in this
study. However, because the same creatinine assay was
used for all repeated measurements for each individual
participant in the study, the effect of using this method to
determine the eGFR slope within individuals is likely
limited.
In addition, a limitation of our study is its relatively
small sample size, especially of some subgroups.Conclusions
In this study, we found that a rapid decrease in the
eGFR is a predictor of mortality in older persons in the
general population The combination of the baseline
eGFR and the eGFR slope allowed the identification of
subgroups of very elderly with higher mortality risks and
subgroups of very elderly with an eGFR of <60 ml/min/
year that do not have an increased risk of mortality. The
combination of the eGFR and the eGFR slope did not
predict a decline in functional performance.
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